CONTEXT AND OBJECTIVE: Neonatal sepsis is associated with premature birth and maternal infection. Large-scale studies seek to define markers that identify neonates at risk of developing sepsis. Here, we examine whether the scientific evidence supports systematic use of polymorphism genotyping in cytokine and innate immunity genes, to identify neonates at increased risk of sepsis. DESIGN AND SETTING: Narrative literature review conducted at Fernandes Figueira Institute, Brazil.
IntRODuCtIOn
Neonatal sepsis, defined by systemic circulatory abnormalities (predominantly peripheral vasoconstriction, oliguria and ischemic damage to inner organs) and a variable spectrum of clinical signs, resulting from invasion of the bloodstream by bacteria and other pathogens, as well as from the ineffective host response, in infants up to their first month of life. 1 It results in one million deaths each year (42% in the first week of life). This amounts to 10% of all mortality under the age of five years. 2 In Brazil, neonatal sepsis is a leading cause of mortality during the neonatal period, which represents an estimated 60% of all childhood mortality. 
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Diversity of infectious exposures is relevant to the clinical differences between early-onset and late-onset neonatal sepsis.
The former is classically associated with pathogens present at the fetal-maternal interface, 10 while the latter (much more frequent) reflects invasion from nosocomial microorganisms, with a risk that increases with the length of hospitalization and invasiveness of procedures, and when microbiological control is suboptimal. 9, 11, 12 The risks of neonatal infection and sepsis are inversely proportional to gestational age, thus suggesting that critical components of the immune system reach maturity only in the final weeks of gestation, 13, 14 just before the newborn needs them to successfully manage the transition from microbiological sterility to colonization by a healthy microbiota. It remains to be established whether the increase in birth weight as gestational age approaches 37 weeks of gestation plays any additional role in protecting the neonate from infection. 14 The variable of clinical evolution of neonatal sepsis is related to individual variability in immune competence, especially with regard to innate immunity, 15 and to differences in responses to therapy. It is difficult to define which infants are at greatest risk of developing sepsis, among those exposed to similar environmental challenges. Even after sepsis has already developed, it remains difficult to monitor it through specific laboratory criteria, since pathogen isolation from blood and other sites is limited by low sensitivity and by the limited amounts that can be sampled. Aggressive antibiotic prophylaxis, on the other hand, significantly increases the risk of drug toxicity in premature infants, who lack efficient renal and hepatic detoxification mechanisms. Consequently, there is still a lack of tests for ensuring early and reliable diagnosing of neonatal sepsis, and for defining the patients who are most likely to benefit from aggressive antimicrobial treatment. 16, 17 A comprehensive review by Härtel et al. 18 addressed the complexities involved in defining the individual differences that influence the risk of neonatal sepsis and related outcomes, especially with regard to specific genes of relevance to the host-pathogen relationship and to the collective influence of gene pools that differ among ethnically diverse populations. These authors acknowledged that host genetic markers with prognostic value for sepsis might be helpful in managing the neonates who would be most likely to benefit from aggressive antimicrobial therapy, and they put the challenges involved into perspective. In addition to the technical difficulties inherent to all genotyping studies, the 
OBJECtIVE
This study aimed to analyze whether the available scientific evidence supports systematic use of genotyping of one or more polymorphisms in cytokine and innate immunity genes as a means of identifying neonates who are at increased risk of sepsis.
MEtHODS
We conducted an online review of the literature, and followed the guidelines provided by Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA 
Study selection for analysis
Case-control studies evaluating the impact of genetic variability on sepsis in newborns were included. The patient group was composed of septic newborns and the control group was composed of healthy newborns or non-septic newborns. The relevant outcome was neonatal sepsis.
We excluded the following: case reports; studies that did not evaluate sepsis as an outcome; methodological reviews and technical studies; studies focusing on children outside of the neonatal age group; studies on genetic diversity of pathogens rather than on patients; and any other papers retrieved that did not match the inclusion criteria.
The abstracts of all studies identified in the original search after combining the descriptors were evaluated. After elimination of all papers that failed to meet the inclusion criteria, the manuscripts were fully analyzed.
All the papers that were subjected to in-depth analysis had been retrieved through the primary PubMed search, even though some of them were also retrieved through the complementary searches in Embase, Lilacs, SciELO and the Cochrane Library.
Quality assessment
Three of the co-authors (Moore DB, Gaspar-Elsas MI and Carvalho JK) independently applied the previously published methodological standards of Bogardus et al. 19 for assessing the quality of molecular genetic studies within the field of clinical epidemiology, following the recommendations of Peters et al. 20 A total of 22 papers were evaluated with regard to the following methodological standards: reproducibility, objectivity, case definition, adequacy of case group spectrum, control group definition, adequacy of the control group and quantitative summary ( Table 2) . 9, We further assessed the quality of the studies by means of the checklist of Downs and Black ( Table 3) . 42 Exclusions were always based on noncompliance with the criteria of the ideal methodological standard. In addition, every study was further examined for possible methodological flaws and interpretation of findings. 
Data analysis
In this step, we aimed to define whether the conclusions in each paper did or did not support the assumption that genotyping of polymorphisms of interest is well-established as a laboratory test for systematic evaluation of the risk of neonatal sepsis and its complications. Data from each of the selected references that were used for this definition were summarized in a descriptive form, excluding technical details and quantitative data, but recording the nature of the evidence, clarity of the measurements, adequacy of the methods, information on potential conflicts of interest and coherence between the actual data and the conclusions and/or recommendations.
RESuLtS
A total of 548 papers were analyzed on the basis of their titles and abstracts, and the following were excluded: 20 technical protocols; 6 reviews; 231 papers that addressed genetic diversity of pathogens, rather than genetic diversity of patients; 198 papers that did not study sepsis as a relevant outcome; 59 studies that comprised age groups other than only neonates; 7 studies that did not address genetic polymorphisms; 2 case reports; 1 study that did not evaluate humans; 1 paper written in Polish, with no English translation; and 1 study that was not available.
The remaining 22 articles were fully analyzed 9,21-41 ( Table 4) .
Their contents were summarized in the following sections, which address different SNPs. In several studies addressing more than one specific polymorphism, the information on each polymorphism is summarized with emphasis proportional to the degree of statistical and epidemiological relevance, as well as to the attention it received in previous studies.
tnF-alpha gene polymorphism
We retrieved four studies addressing the association between the SNP TNF-308 and development of neonatal sepsis. et al., the septic patients presenting AA/GA genotypes had a mortality rate from sepsis that was three times greater than among those presenting the GG genotype. 37 The remaining doubts about the lack of association between the SNP TNF-308 and development of neonatal sepsis, which had persisted mainly due to the limited sample size of the studies carried out earlier, were subsequently ruled out by a study on 2870 VLBW infants. 9 This study had the following strong points, besides the large cohort size: a) genotyping supported by functional studies; b) stringent criteria for sepsis (microbiologically-proven); and c) confirmation of Hardy-Weinberg equilibrium. Its limitations were: a) no assessment of ethnicity; and b) limited microbiological information.
Thus, although being a carrier of the SNP TNF-308A was shown to increase the risk of sepsis in a meta-analysis that included mostly adults and older children, 44 there is so far no evidence of any association between the SNP TNF-308 G/A and increased risk of sepsis during the neonatal period.
Questions (Q)
Aydemir et al. 21 Härtel et al. 9 Abu-Maziad et al. 22 Auriti et al. 23 Koroglu et al. 24 Spiegler et al. 25 Abdel-Hady et al. 26 Bertalan et al. 27 Reiman et al. 28 Dzwonek et al. 29 van Der Zwet et al. 30 Schueller et al. 31 Derzbach et al. 32 Härtel et al. 33 Baier et al. 34 Göpel et al.
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John Baier et al. 36 Hedberg et al. 37 Ahrens et al. 38 Bessler et al. 39 Harding et al. 40 treszl et al. 41 Q 1 yes yes yes yes yes yes yes yes yes yes yes yes yes yes yes yes yes yes yes yes yes yes Q 2 yes yes yes yes yes yes yes yes yes yes yes yes yes yes yes yes yes yes yes yes yes yes Q 3 yes yes yes yes yes yes yes yes yes yes yes yes yes yes yes yes yes yes yes yes yes yes Q 4 yes yes yes yes yes yes yes yes yes yes yes yes yes yes yes yes yes yes yes yes yes yes Q 5 yes yes yes yes yes yes yes yes yes yes yes yes yes yes yes yes yes yes yes yes yes yes Q 6 yes yes yes yes yes yes yes yes yes yes yes yes yes yes yes yes yes yes yes yes yes yes Q 10 no yes yes yes yes yes yes yes yes yes no yes yes yes yes yes yes yes yes yes yes no Down and Black checklist for assessing study quality. Q 1 = Is the hypothesis/aim/objective of the study clearly described?; Q 2 = Are the main outcomes to be measured clearly described in the Introduction or Methods section?; Q 3 = Are the characteristics of the patients included in the study clearly described?; Q 4 = Are the interventions of interest clearly described?; Q 5 = Are the distributions of principal confounders in each group of subjects to be compared clearly described?; Q 6 = Are the main findings of the study clearly described?; Q 7 = Does the study provide estimates of the random variability in the data for the main outcomes?; Q 8 = Have all important adverse events that may be a consequence of the intervention been reported?; Q 9 = Have the characteristics of patients lost to follow-up been described? Q 10 = Have actual probability values been reported (e.g. 0.035 rather than < 0.05) for the main outcomes except where the probability value is less than 0.001?; Q 11 = Were the subjects asked to participate in the study representative of the entire population from which they were recruited?; Q 12 = Were those subjects who were prepared to participate representative of the entire population from which they were recruited?; Q 13 = Were the staff, places, and facilities where the patients were treated, representative of the treatment the majority of patients receive?; Q 14 = Was an attempt made to blind study subjects to the intervention they have received?; Q 15 = Was an attempt made to blind those measuring the main outcomes of the intervention?; Q 16 = If any of the results of the study were based on "data dredging", was this made clear?; Q 17 = In trials and cohort studies, do the analyses adjust for different lengths of follow-up of patients, or in case-control studies, is the time period between the intervention and outcome the same for cases and controls?; Q 18 = Were the statistical tests used to assess the main outcomes appropriate?; Q 19 = Was compliance with the intervention/s reliable?; Q 20 = Were the main outcome measurements used accurate (valid and reliable)?; Q 21 = Were the patients in different intervention groups (trials and cohort studies) or were the cases and controls (case-control studies) recruited from the same population?; Q 22 = Were study subjects in different intervention groups (trials and cohort studies) or were the cases and controls (case-control studies) recruited over the same period of time?; Q 23 = Were study subjects randomized to intervention groups?; Q 24 = Was the randomized intervention assignment concealed from both patients and healthcare staff until recruitment was complete and irrevocable?; Q 25 = Was there adequate adjustment for confounding in the analyses from which the main findings were drawn?; Q 26 = Were losses of patients from follow-up taken into account?; Q 27 = Did the study have sufficient power to detect a clinically important effect where the probability value for a difference being due to chance is less than 5% 
Interleukin-6 gene polymorphism
Six studies addressing the association between the SNP IL-6-174 and neonatal sepsis were identified. Two of them showed that there was a small risk associated with the SNP IL-6-174 C allele and neonatal sepsis. The first study 40 This study also showed that the higher rate of sepsis in this group reflected higher infection rates due to Gram-positive organisms, and that sepsis was not detected in patients who had been given prophylaxis using teicoplanin.
Apparently contradictory results were seen by Baier et al. 34 in a study that included 293 VLBW infants (< 1500 g; comprising 233 African-American, 57 Caucasian and three Latin-American infants) who underwent mechanical ventilation. This study showed that the IL-6-174 C allele was associated with increased incidence of sepsis. However, this effect was observed only in African-American subjects and not in Caucasian subjects. With a small cohort of 33 septic, 35 infected and 35 healthy VLBW infants, Treszl et al. 41 also failed to detect an association. Another study, with a large cohort that included 1206 VLBW preterm infants, mostly Caucasian, was equally unable to show any association between the SNP IL-6-174 and neonatal sepsis. 35 The strong points in this study included: a) large cohort size; b) careful microbiological characterization of bloodstream infections and colonization; and c) stringent criteria for sepsis. Recently, data from these five studies were consolidated into a meta-analysis 45 
Mannose-binding lectin polymorphism
Mannose-binding lectin (MBL) is a human collectin and an important protein in the humoral innate immune system. MBL is a circulating pattern-recognition molecule that recognizes carbohydrate structures on the surface of a wide range of microorganisms, including bacteria, viruses, yeasts, protozoa and multicellular parasites, and thereby provides first-line defense. It also activates the complement system through a distinctive third pathway, independent of both antibody and C1 components. 28, 46 Our search retrieved five studies that addressed the impact of MBL polymorphism and neonatal sepsis, but none of them identified any association between this genetic polymorphism and neonatal sepsis. A study that included 742 neonates did not find any association between MBL2 gene polymorphism and neonatal sepsis. 30 The strong points of this study were firstly its large cohort size and secondly good microbiological characterization of sepsis cases. Interestingly, the authors suggested that the possible cause of the lack of association could be a reflection of the predominance of bloodstream infections due to coagulase-negative staphylococci.
MBL is not very helpful against these organisms.
Similar negative results were found in another study carried out on 158 preterm infants. 29 In this study, predominance of infection by coagulase-negative staphylococci was also observed.
One important finding was the demonstration that MBL level, low birth weight and low gestational age were independently associated with the risk of sepsis. The probability of sepsis in neonates of < 28 weeks or < 1000 g with MBL levels < 400 ng/ml was found to be 70% in that study; in contrast, for those with MBL levels above 400 ng/ml, the risk of sepsis was 47%.
Auriti et al. 23 also showed, in a prospective study on 365 neonates, that the median MBL concentration on admission was significantly lower in infected than in non-infected neonates (P < 0.001). Moreover, they showed that lower levels of MBL on admission were associated with an increased risk of infection, independently of gestational age and invasive procedures.
Another interesting finding in this study resulted from strati- healthy premature neonates did not find any association between MBL2 gene polymorphism and nosocomial invasive fungal infection. 21 Negative results were also found by Koroglu et al. 24 on 99 premature neonates, in which sepsis was defined by microbiological identification of pathogens in blood cultures. However, when clinical sepsis was the outcome, the frequency of sepsis was higher in the group of infants with MBL gene polymorphism than among infants with wildtype MBL genotype (61.2 versus 31.7%, respectively, P = 0.008).
Thus, there is so far no evidence that MBL2 gene polymorphism is associated with neonatal sepsis. 24 Several studies have shown that carrier status for allele 2 of the IL-1ra (IL-1raA2) SNP is associated with greater production of IL-1ra and IL-1β in vivo and in vitro. [47] [48] [49] The single study identified in our search 39 was carried out on 95 premature neonates (24-35 weeks of gestational age) and, despite confirming that IL-1ra gene polymorphism had an impact on preterm delivery, it failed to document any impact on early-onset sepsis. The strong points of this study included: a) ethnicity clearly defined; b) gestational age carefully determined; c) a small difference in gestational age (29-32 weeks) between preterm and healthy infants, but reflected in clear differences in birth weight; d) good clinical and microbiological definition of sepsis; and e) incorporation of extra data from adults in an unrelated German study.
Selectin polymorphism
Only one study addressing selectin polymorphism was retrieved. were genotyped. 22 The subjects were stratified into three groups There have been no instances in which a large cohort study was the first to identify a major effect on susceptibility to sepsis from any of the candidate genes, although strong effects on predisposing conditions such as premature birth 39 could be identified through this approach.
Importantly, this stalemate is not dependent on the exact methodology used. For example, one study 22 used a family-based approach (transmission disequilibrium test) to identify multiple candidate genes associated with neonatal sepsis in a relatively large cohort of infants, and was able to detect moderate to borderline associations with a number of genes (PLA2, TLR subtypes and IL-10). Additional strategies used the definition of septic "phenotypes" based on multiple parameters to improve sensitivity, taking care to correct for the effect of multiple comparisons. None of the most frequently studied polymorphisms in other studies (TNF or IL-6) made it into the list of promising candidates, although PLA2, TLR and IL-10 all fall within the category of immune and inflammatory genes. It is unclear, however, whether a strategy that was developed to explore genotype/phenotype relationships is appropriate for sepsis, which cannot rigorously be considered to be a "phenotype", since it is a rapidly evolving clinical condition, entirely dependent on infectious exposure that can neither be controlled, nor ruled out.
One important aspect of these studies involves the ethnic diversity of the populations examined. In at least one well-controlled study, 34 ethnicity played a major role in modifying associations between polymorphisms in immunologically relevant genes (IL-6 and CD14) and sepsis-related outcomes.
Ethnicity is an issue in other studies conducted in Israel, 39 Interpretations on genotyping data are likely to be affected by the ethnic makeup of the population of interest, and this represents a limiting factor for applying this approach to infants worldwide.
Another major issue is the complexity of the polymorphisms involved, which may be quite variable, from single nucleotide polymorphisms in the case of TNF-alpha 8 to complex insertion and deletion events in the case of ACE. 36 The complexity is highest in the case of MBL, 34 given allele in the TNF-alpha system results in significantly reduced transcription rates and decreased protein release was achieved in a non-physiological ex vivo assay. 51 While it is possible that this reflects physiological potential in the context of sepsis, the latter is much more difficult to ascertain. Other related problems concern the relative impact of single polymorphisms in the TNF region of the MHC on both TNF-α and TNF-β; 31 and the interrelated effects of polymorphisms in IL-1RA on production of IL-1RA and of IL-1β. 39 One especially entangled situation concerns MBL. 24, 29 This protein presents a series of polymorphisms that interfere with assembly of functional multimers. As a consequence, individuals who are homozygous for any given mutation, or heterozygous for two distinct mutations, present severe deficiency in this innate microbicidal factor. However, heterozygotes possessing one wildtype allele may produce functional MBL multimers and, since exposure to pathogens stimulates MBL production, deficiency
may be difficult to demonstrate. Here, more than anywhere else, the dissociation between genotype and its phenotypic effects is a major issue. Indeed, the clinically relevant issue is not which alleles an infant possesses, but how much functional MBL is produced. The discrepancies in the results between studies carried out in ethnically diverse populations 24, 29, 30 may be difficult to reconcile without systematic evaluation of the circulating MBL levels. However, there is a good side to this, because measurement of MBL may eventually prove to be a better predictor of sepsis than genotyping and, as a corollary, MBL replacement therapy should be helpful in individuals lacking it. One important issue
that cannot be settled at present is whether MBL administration to infants who are utterly lacking in functional multimers might induce antibodies to the exogenous protein.
COnCLuSIOn
Genotyping of polymorphisms in the context of neonatal sepsis should be focused on a few markers, in order to reduce labor and costs, and to maximize speed, which is essential in the intensive care setting. While target polymorphisms should be strongly associated with the outcome, in most or all susceptible neonates, the extant literature shows that critical reevaluation of this approach is necessary, since many genes have an impact on sepsis, but none of them meets these requirements. Most importantly, genotyping more than a few of them would be impractical, since their relevance to the decision-making process is difficult to determine. We suggest, instead, that once candidate polymorphisms have been identified in epidemiological studies, their functional relevance should be established, before recommendations for their clinical routine use as genotypic markers are made.
